Neurotheranostics as Personalized Medicines

The Bioimaging section (page unavailable) describes rapid assessment of pharmacokinetics and biodistribution, while the Blood brain barrier section describes real-time imaging to evaluate drug biodistribution and localization at target sites. The paper supports targeted local treatment, but it does not specifically say that pharmacokinetics can be tracked in real time. (LLM, conf=0.82)

In “AD and theranostics” (page unavailable), the review describes an elevated MRI signal in mice imaged four days after injection. It does not say the signal peaked then or establish that optimal imaging windows span hours to days. (LLM, conf=0.87)

In “Therapeutics that facilitate neuroprotection and neuroregeneration” (page not provided), the review reports that maternal nanoparticle exposure may harm fetal development and that titanium oxide nanoparticles affected genes associated with mouse brain development. That supports concern about developmental effects, but it does not establish the unqualified claim that titanium oxide disrupts fetal brain development generally. (LLM, conf=0.83)

The section “Therapeutics that facilitate neuroprotection and neuroregeneration” (page unavailable) identifies a risk of nanoparticle toxicity. The AD section (page unavailable) says some AD drug candidates cause unacceptable toxicities. Neither passage says nanoparticle toxicity is unacceptable specifically because AD requires long-term treatment, or contrasts that risk with toxicity being justified in oncology. (LLM, conf=0.85)

The section “Therapeutics that facilitate neuroprotection and neuroregeneration” reports that zinc oxide nanoparticles induced necrosis and apoptosis in murine macrophages. The citing sentence omits the nanoparticle form and murine qualification, making it broader than the reported finding. (LLM, conf=0.82)